The metastatic castration-resistant prostate cancer market is poised for substantial growth over the coming years, driven by the rising prevalence of advanced prostate cancer and continuous innovation in treatment options. Additionally, the ongoing late-stage clinical development of…
Source: prnewswire
Country: United States